AstraZeneca (AZN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncology/Respiratorysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.17% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
- AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
- AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership
- Astrazeneca (AZN) Rises Higher Than Market: Key Facts
- AstraZeneca (LSE:AZN) Enters AI Drug Discovery Partnership In MASH And Cardiomyopathies
- RBC keeps AstraZeneca at ‘outperform’ ahead of AVANZAR lung cancer trial
- AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know
- The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AstraZeneca.
Full AZN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.